or
forgot password
  • cancer clinical trials in farmington, MI

  • A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
    Michigan Institute for Neurological Disorders
    Farmington, Michigan 48334
    Multiple Sclerosis, Relapsing-Remitting